{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T13:52:07Z","timestamp":1792072327310,"version":"4.4.0"},"reference-count":326,"publisher":"Rockefeller University Press","issue":"11","license":[{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/rupress.org\/pages\/terms102024\/"}],"funder":[{"DOI":"10.13039\/100008363","name":"Danish Cancer Society","doi-asserted-by":"publisher","award":["R-257-A14720"],"award-info":[{"award-number":["R-257-A14720"]}],"id":[{"id":"10.13039\/100008363","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008363","name":"Danish Cancer Society","doi-asserted-by":"publisher","award":["R339-A19782"],"award-info":[{"award-number":["R339-A19782"]}],"id":[{"id":"10.13039\/100008363","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008363","name":"Danish Cancer Society","doi-asserted-by":"publisher","award":["R390-A23578"],"award-info":[{"award-number":["R390-A23578"]}],"id":[{"id":"10.13039\/100008363","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010733","name":"Danish Childhood Cancer Foundation","doi-asserted-by":"publisher","award":["2019-5934"],"award-info":[{"award-number":["2019-5934"]}],"id":[{"id":"10.13039\/100010733","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010733","name":"Danish Childhood Cancer Foundation","doi-asserted-by":"publisher","award":["2020-5769"],"award-info":[{"award-number":["2020-5769"]}],"id":[{"id":"10.13039\/100010733","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Neye Foundation"},{"name":"Arkitekt Lars N\u00f8rvigs Fond"}],"content-domain":{"domain":["rupress.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,11,2]]},"abstract":"<jats:p>Immunologically cold tumors remain a major obstacle to effective cancer immunotherapy because they lack sufficient immune infiltration and fail to sustain productive antitumor immune responses. Although substantial progress has been made in understanding the mechanisms underlying immune evasion, only a minority of patients achieve durable benefit from current immunotherapeutic approaches. In this review, we discuss emerging strategies aimed at converting cold tumors into immune-responsive lesions by enhancing tumor antigenicity and promoting effective immune priming. We examine how these approaches may cooperate with interventions that induce immunogenic cell death, improve T cell trafficking, reverse immunosuppression, and remodel the tumor microenvironment. We further discuss advanced synthetic immunotherapeutic strategies designed to overcome multiple layers of immune resistance. Collectively, current evidence suggests that no single mechanism is sufficient to drive durable cold-to-hot tumor conversion, highlighting the need for integrated therapeutic approaches capable of simultaneously targeting distinct biological barriers to antitumor immunity.<\/jats:p>","DOI":"10.1084\/jem.20260378","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T06:20:56Z","timestamp":1789626056000},"update-policy":"https:\/\/doi.org\/10.1084\/jem.crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Turning cold tumors hot: Strategies to enhance antitumor immunity"],"prefix":"10.1084","volume":"223","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-8378-4257","authenticated-orcid":true,"given":"Viktor German","family":"Steffensen","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03ytt7k16","id-type":"ROR","asserted-by":"publisher"}],"name":"Cancer and Medicine, Danish Cancer Institute 1 , Copenhagen,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8380-7340","authenticated-orcid":true,"given":"Mojca","family":"Bratina","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03ytt7k16","id-type":"ROR","asserted-by":"publisher"}],"name":"Cancer and Medicine, Danish Cancer Institute 1 , Copenhagen,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4052-9614","authenticated-orcid":true,"given":"Christina","family":"Tsiavou","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03ytt7k16","id-type":"ROR","asserted-by":"publisher"}],"name":"Cancer and Medicine, Danish Cancer Institute 1 , Copenhagen,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0829-4993","authenticated-orcid":true,"given":"Kjeld","family":"Schmiegelow","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05bpbnx46","id-type":"ROR","asserted-by":"publisher"}],"name":"Copenhagen University Hospital 2 Department of Pediatrics and Adolescents Medicine, , Rigshospitalet,","place":["Denmark"]},{"id":[{"id":"https:\/\/ror.org\/05bpbnx46","id-type":"ROR","asserted-by":"publisher"}],"name":"Institute of Clinical Medicine, University of Copenhagen 3 Faculty of Medicine, , Rigshospitalet,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9454-402X","authenticated-orcid":true,"given":"Daniela","family":"De Zio","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03ytt7k16","id-type":"ROR","asserted-by":"publisher"}],"name":"Cancer and Medicine, Danish Cancer Institute 1 , Copenhagen,","place":["Denmark"]},{"id":[{"id":"https:\/\/ror.org\/03yrrjy16","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Southern Denmark 4 Department of Cancer and Inflammation Research, Institute of Molecular Medicine, , Odense,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"291","published-online":{"date-parts":[[2026,10,15]]},"reference":[{"key":"2026101509311866700_bib1","doi-asserted-by":"publisher","first-page":"e545","DOI":"10.1016\/S1470-2045(24)00407-8","article-title":"Radiotherapy and theranostics: A Lancet Oncology Commission","volume":"25","author":"Abdel-Wahab","year":"2024","journal-title":"Lancet Oncol."},{"key":"2026101509311866700_bib2","doi-asserted-by":"publisher","first-page":"102978","DOI":"10.1016\/j.ctrv.2025.102978","article-title":"Immunocytokines in cancer treatment: A systematic review","volume":"139","author":"Agliardi","year":"2025","journal-title":"Cancer Treat. Rev."},{"key":"2026101509311866700_bib3","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/s12934-025-02838-2","article-title":"Bacteria-based immunosuppressive tumor microenvironment reprogramming: A promising dawn in cancer therapy","volume":"24","author":"Akbariqomi","year":"2025","journal-title":"Microb. Cell Fact."},{"key":"2026101509311866700_bib4","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"key":"2026101509311866700_bib5","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20250378","article-title":"Microbiota-centered interventions to boost immune checkpoint blockade therapies","volume":"222","author":"Almonte","year":"2025","journal-title":"J. Exp. Med."},{"key":"2026101509311866700_bib6","doi-asserted-by":"publisher","first-page":"26933","DOI":"10.1038\/s41598-025-11990-z","article-title":"A hexamerization-enhanced, Fc-silenced agonistic CD27 antibody amplifies T-cell effector functions as single agent and in combination with PD-1 blockade","volume":"15","author":"Alt\u0131nta\u015f","year":"2025","journal-title":"Sci. Rep."},{"key":"2026101509311866700_bib7","doi-asserted-by":"publisher","first-page":"1736806","DOI":"10.3389\/fimmu.2026.1736806","article-title":"Anti-angiogenic therapies in cancer: From endogenous inhibitors to bispecific VEGF x PD-(L)1 antibodies","volume":"17","author":"\u00c1lvarez-Vallina","year":"2026","journal-title":"Front. Immunol."},{"key":"2026101509311866700_bib8","doi-asserted-by":"publisher","first-page":"9553","DOI":"10.1200\/jco.2024.42.16_suppl.9553","article-title":"Phase II trial of weekly or bi-weekly tocilizumab with ipilimumab and nivolumab in advanced melanoma: Clinical outcomes and biomarker analysis","volume":"42","author":"Anouti","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"2026101509311866700_bib9","doi-asserted-by":"publisher","first-page":"7051","DOI":"10.1038\/s41598-023-32850-8","article-title":"An intuitionistic approach for the predictability of anti-angiogenic inhibitors in cancer diagnosis","volume":"13","author":"Ansar","year":"2023","journal-title":"Sci. Rep."},{"key":"2026101509311866700_bib10","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"2026101509311866700_bib11","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1038\/s43018-025-00979-2","article-title":"Tumor antigens preferentially derive from unmutated genomic sequences in melanoma and non-small cell lung cancer","volume":"6","author":"Apavaloaei","year":"2025","journal-title":"Nat. Cancer"},{"key":"2026101509311866700_bib12","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.ccell.2018.02.010","article-title":"Fc effector function contributes to the activity of human anti-CTLA-4 antibodies","volume":"33","author":"Arce Vargas","year":"2018","journal-title":"Cancer Cell"},{"key":"2026101509311866700_bib13","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/nature24462","article-title":"Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer","volume":"551","author":"Balachandran","year":"2017","journal-title":"Nature"},{"key":"2026101509311866700_bib14","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1136\/jitc-2023-SITC2023.0641","article-title":"641 A pilot study of a DNAJB1-PRKACA fusion kinase peptide vaccine combined with nivolumab and ipilimumab for patients with fibrolamellar hepatocellular carcinoma","volume":"11","author":"Baretti","year":"2023","journal-title":"BMJ J. Immunotherapy Cancer"},{"key":"2026101509311866700_bib15","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/s43018-026-01153-y","article-title":"Oncolytic viruses and cytokine-based gene therapies reprogram the tumor microenvironment","volume":"7","author":"Bernstock","year":"2026","journal-title":"Nat. Cancer"},{"key":"2026101509311866700_bib16","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat. Med."},{"key":"2026101509311866700_bib17","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1158\/2159-8290.CD-26-0003","article-title":"Pharmacologic inhibition of PMS2 induces MMR deficiency and response to immune checkpoint blockade","volume":"16","author":"Blagg","year":"2026","journal-title":"Cancer Discov."},{"key":"2026101509311866700_bib18","doi-asserted-by":"publisher","first-page":"15287","DOI":"10.1038\/s41598-023-42495-2","article-title":"The impact of mutational clonality in predicting the response to immune checkpoint inhibitors in advanced urothelial cancer","volume":"13","author":"Boll","year":"2023","journal-title":"Sci. Rep."},{"key":"2026101509311866700_bib19","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1001\/jama.2024.19462","article-title":"CAR T cells and T-cell therapies for cancer: A translational science review","volume":"332","author":"Brudno","year":"2024","journal-title":"JAMA"},{"key":"2026101509311866700_bib20","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41571-024-00932-9","article-title":"Tumour mutational burden: Clinical utility, challenges and emerging improvements","volume":"21","author":"Budczies","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2026101509311866700_bib21","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.cell.2018.01.004","article-title":"NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control","volume":"172","author":"B\u00f6ttcher","year":"2018","journal-title":"Cell"},{"key":"2026101509311866700_bib22","doi-asserted-by":"publisher","first-page":"9029","DOI":"10.1038\/s41467-025-64081-y","article-title":"A next-generation anti-CTLA-4 probody mitigates toxicity and enhances anti-tumor immunity in mice","volume":"16","author":"Cao","year":"2025","journal-title":"Nat. Commun."},{"key":"2026101509311866700_bib23","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/s41580-025-00841-4","article-title":"Mechanisms and regulation of DNA end resection in the maintenance of genome stability","volume":"26","author":"Ceccaldi","year":"2025","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2026101509311866700_bib24","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1158\/2326-6066.CIR-13-0123","article-title":"STING ligand c-di-GMP improves cancer vaccination against metastatic breast cancer","volume":"2","author":"Chandra","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"2026101509311866700_bib25","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.ccell.2025.12.011","article-title":"B cells disrupt tertiary lymphoid structure formation and suppress anti-tumor immunity","volume":"44","author":"Chen","year":"2026","journal-title":"Cancer Cell"},{"key":"2026101509311866700_bib26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: The cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"2026101509311866700_bib27","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1200\/JCO.23.01965","article-title":"Randomized phase II study of nab-paclitaxel and gemcitabine with or without tocilizumab as first-line treatment in advanced pancreatic cancer: Survival and cachexia","volume":"43","author":"Chen","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"2026101509311866700_bib28","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.ccell.2025.02.010","article-title":"Low-dose irradiation of the gut improves the efficacy of PD-L1 blockade in metastatic cancer patients","volume":"43","author":"Chen","year":"2025","journal-title":"Cancer Cell"},{"key":"2026101509311866700_bib29","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010212","article-title":"FAP-targeted radioligand therapy with (68)Ga\/(177)Lu-DOTA-2P(FAPI)2 enhance immunogenicity and synergize with PD-L1 inhibitors for improved antitumor efficacy","volume":"13","author":"Chen","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"2026101509311866700_bib30","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/nri3405","article-title":"Molecular mechanisms of T cell co-stimulation and co-inhibition","volume":"13","author":"Chen","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"2026101509311866700_bib31","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/cmi.2017.30","article-title":"The functions of tumor suppressor PTEN in innate and adaptive immunity","volume":"14","author":"Chen","year":"2017","journal-title":"Cell. Mol. Immunol."},{"key":"2026101509311866700_bib32","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1016\/j.jtho.2025.02.029","article-title":"Selective depletion of CCR8+Treg cells enhances the antitumor immunity of cytotoxic T cells in lung cancer by dendritic cells","volume":"20","author":"Chen","year":"2025","journal-title":"J. Thorac. Oncol."},{"key":"2026101509311866700_bib33","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1038\/ni.3558","article-title":"Regulation and function of the cGAS-STING pathway of cytosolic DNA sensing","volume":"17","author":"Chen","year":"2016","journal-title":"Nat. Immunol."},{"key":"2026101509311866700_bib34","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1084\/jem.20030152","article-title":"Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3","volume":"198","author":"Chen","year":"2003","journal-title":"J. Exp. Med."},{"key":"2026101509311866700_bib35","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s40364-021-00312-w","article-title":"Antiangiogenic therapy reverses the immunosuppressive breast cancer microenvironment","volume":"9","author":"Chen","year":"2021","journal-title":"Biomark Res."},{"key":"2026101509311866700_bib36","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1038\/s41388-025-03454-5","article-title":"Post-translational modifications in DNA damage repair: Mechanisms underlying temozolomide resistance in glioblastoma","volume":"44","author":"Chen","year":"2025","journal-title":"Oncogene"},{"key":"2026101509311866700_bib37","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1002\/1878-0261.12739","article-title":"Prevalence of PRKDC mutations and association with response to immune checkpoint inhibitors in solid tumors","volume":"14","author":"Chen","year":"2020","journal-title":"Mol. Oncol."},{"key":"2026101509311866700_bib38","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1200\/JCO.22.00343","article-title":"Randomized, double-blind, placebo-controlled, global phase III trial of talimogene laherparepvec combined with pembrolizumab for advanced melanoma","volume":"41","author":"Chesney","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"2026101509311866700_bib39","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus Cabozantinib versus Sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"2026101509311866700_bib40","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1086\/315497","article-title":"Biodistribution and genetic stability of the novel antitumor agent VNP20009, a genetically modified strain of Salmonella typhimurium","volume":"181","author":"Clairmont","year":"2000","journal-title":"J. Infect. Dis."},{"key":"2026101509311866700_bib41","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aav5989","article-title":"Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy","volume":"11","author":"Claus","year":"2019","journal-title":"Sci. Transl Med."},{"key":"2026101509311866700_bib42","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/s41586-022-05192-0","article-title":"PD-1-cis IL-2R agonism yields better effectors from stem-like CD8+ T cells","volume":"610","author":"Codarri Deak","year":"2022","journal-title":"Nature"},{"key":"2026101509311866700_bib43","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adr9382","article-title":"Chimeric antigen receptor T cells against the IGHV4-34 B cell receptor specifically eliminate neoplastic and autoimmune B cells","volume":"18","author":"Cohen","year":"2026","journal-title":"Sci. Transl Med."},{"key":"2026101509311866700_bib44","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1158\/2767-9764.CRC-25-0566","article-title":"Phase 1b study of dazostinag plus pembrolizumab after Hypofractionated radiotherapy in patients with select advanced solid tumors","volume":"5","author":"Cooper","year":"2025","journal-title":"Cancer Res. Commun."},{"key":"2026101509311866700_bib45","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/s41573-026-01442-2","article-title":"Realizing the potential of agonistic antibody immunotherapy","volume":"25","author":"Cragg","year":"2026","journal-title":"Nat. Rev. Drug Discov."},{"key":"2026101509311866700_bib46","doi-asserted-by":"publisher","first-page":"1075593","DOI":"10.3389\/fonc.2023.1075593","article-title":"A systematic review and meta-analysis evaluating the impact of antibiotic use on the clinical outcomes of cancer patients treated with immune checkpoint inhibitors","volume":"13","author":"Crespin","year":"2023","journal-title":"Front. Oncol."},{"key":"2026101509311866700_bib47","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.ejphar.2014.07.025","article-title":"Cisplatin in cancer therapy: Molecular mechanisms of action","volume":"740","author":"Dasari","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"2026101509311866700_bib48","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"2026101509311866700_bib49","doi-asserted-by":"publisher","first-page":"111943","DOI":"10.1016\/j.isci.2025.111943","article-title":"DNA-PK inhibition sustains the antitumor innate immune response in small cell lung cancer","volume":"28","author":"De Rosa","year":"2025","journal-title":"iScience"},{"key":"2026101509311866700_bib50","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1038\/s41586-022-05593-1","article-title":"\u03b3\u03b4 T cells are effectors of immunotherapy in cancers with HLA class I defects","volume":"613","author":"de Vries","year":"2023","journal-title":"Nature"},{"key":"2026101509311866700_bib51","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.molmed.2022.09.007","article-title":"Dysfunctional tRNA reprogramming and codon-biased translation in cancer","volume":"28","author":"Dedon","year":"2022","journal-title":"Trends Mol. Med."},{"key":"2026101509311866700_bib52","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s00432-025-06087-z","article-title":"Immunogenic dying cells elicit potent anti-tumor T cell immunity against lung metastasis and tumorigenesis","volume":"151","author":"Deng","year":"2025","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"2026101509311866700_bib53","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.immuni.2014.10.019","article-title":"STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors","volume":"41","author":"Deng","year":"2014","journal-title":"Immunity"},{"key":"2026101509311866700_bib54","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41571-020-0403-1","article-title":"TGF\u03b2 biology in cancer progression and immunotherapy","volume":"18","author":"Derynck","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2026101509311866700_bib55","doi-asserted-by":"publisher","first-page":"4756","DOI":"10.1200\/JCO.23.00172","article-title":"Bempegaldesleukin plus nivolumab in untreated advanced melanoma: The open-label, phase III PIVOT IO 001 trial results","volume":"41","author":"Diab","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"2026101509311866700_bib56","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/j.jhep.2020.11.037","article-title":"CD40-mediated immune cell activation enhances response to anti-PD-1 in murine intrahepatic cholangiocarcinoma","volume":"74","author":"Diggs","year":"2021","journal-title":"J. Hepatol."},{"key":"2026101509311866700_bib57","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adg7740","article-title":"Guanosine diphosphate-mannose suppresses homologous recombination repair and potentiates antitumor immunity in triple-negative breast cancer","volume":"16","author":"Ding","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"2026101509311866700_bib58","doi-asserted-by":"publisher","first-page":"6532","DOI":"10.1038\/s41467-025-61675-4","article-title":"Living therapeutics of nonpathogenic bacteria as biosynthesis factory and active carriers for enhancing tumor-targeted therapy","volume":"16","author":"Dong","year":"2025","journal-title":"Nat. Commun."},{"key":"2026101509311866700_bib59","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009710","article-title":"Novel bispecific antibody-drug conjugate targeting PD-L1 and B7-H3 enhances antitumor efficacy and promotes immune-mediated antitumor responses","volume":"12","author":"Dong","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"2026101509311866700_bib60","doi-asserted-by":"publisher","first-page":"5514","DOI":"10.1158\/1078-0432.CCR-16-1673","article-title":"Fractionated radiation therapy stimulates antitumor immunity mediated by both resident and infiltrating polyclonal T-cell populations when combined with PD-1 blockade","volume":"23","author":"Dovedi","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"2026101509311866700_bib61","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.ccell.2025.03.019","article-title":"CAR-T therapy in solid tumors","volume":"43","author":"Du","year":"2025","journal-title":"Cancer Cell"},{"key":"2026101509311866700_bib62","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1038\/s41591-025-04186-5","article-title":"Fecal microbiota transplantation plus immunotherapy in non-small cell lung cancer and melanoma: The phase 2 FMT-LUMINate trial","volume":"32","author":"Duttagupta","year":"2026","journal-title":"Nat. Med."},{"key":"2026101509311866700_bib63","doi-asserted-by":"publisher","first-page":"102353","DOI":"10.1016\/j.xcrm.2025.102353","article-title":"CAR-T cells in solid tumors: Challenges and breakthroughs","volume":"6","author":"Escobar","year":"2025","journal-title":"Cell Rep. Med."},{"key":"2026101509311866700_bib64","doi-asserted-by":"publisher","first-page":"830","DOI":"10.3324\/haematol.2017.176362","article-title":"MSH6 haploinsufficiency at relapse contributes to the development of thiopurine resistance in pediatric B-lymphoblastic leukemia","volume":"103","author":"Evensen","year":"2018","journal-title":"Haematologica"},{"key":"2026101509311866700_bib65","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/nature10169","article-title":"Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells","volume":"475","author":"Facciabene","year":"2011","journal-title":"Nature"},{"key":"2026101509311866700_bib66","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2013598118","article-title":"Epigenetic reprogramming of tumor cell-intrinsic STING function sculpts antigenicity and T cell recognition of melanoma","volume":"118","author":"Falahat","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2026101509311866700_bib67","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-012717","article-title":"Abscopal effects in patients with malignant melanoma treated with radiotherapy and immune checkpoint inhibition: Analysis of a large observational multicenter study","volume":"13","author":"Ferdinandus","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"2026101509311866700_bib68","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/s41586-020-2611-3","article-title":"cDC1 prime and are licensed by CD4+ T cells to induce anti-tumour immunity","volume":"584","author":"Ferris","year":"2020","journal-title":"Nature"},{"key":"2026101509311866700_bib69","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-026-00358-6","article-title":"Innovative CAR-T therapy destroys cancer cells without dangerous side effects","author":"Fieldhouse","year":"2026","journal-title":"Nature"},{"key":"2026101509311866700_bib70","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"2026101509311866700_bib71","doi-asserted-by":"publisher","first-page":"3378","DOI":"10.1158\/0008-5472.CAN-24-3037","article-title":"Plasticity and functional heterogeneity of cancer-associated fibroblasts","volume":"85","author":"Flynn","year":"2025","journal-title":"Cancer Res."},{"key":"2026101509311866700_bib72","first-page":"5188","article-title":"Sparse initial entrapment of systemically injected Salmonella typhimurium leads to heterogeneous accumulation within tumors","volume":"63","author":"Forbes","year":"2003","journal-title":"Cancer Res."},{"key":"2026101509311866700_bib73","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1084\/jem.20101159","article-title":"Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells","volume":"208","author":"Fuertes","year":"2011","journal-title":"J. Exp. Med."},{"key":"2026101509311866700_bib74","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000337","article-title":"Consensus guidelines for the definition, detection and interpretation of immunogenic cell death","volume":"8","author":"Galluzzi","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"2026101509311866700_bib75","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","article-title":"Approaches to treat immune hot, altered and cold tumours with combination immunotherapies","volume":"18","author":"Galon","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"2026101509311866700_bib76","doi-asserted-by":"publisher","first-page":"101393","DOI":"10.1016\/j.xcrm.2024.101393","article-title":"Immunomodulatory effects and improved outcomes with cisplatin- versus carboplatin-based chemotherapy plus atezolizumab in urothelial cancer","volume":"5","author":"Galsky","year":"2024","journal-title":"Cell Rep. Med."},{"key":"2026101509311866700_bib77","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1016\/j.immuni.2025.05.019","article-title":"Regulatory T cell depletion promotes myeloid cell activation and glioblastoma response to anti-PD1 and tumor-targeting antibodies","volume":"58","author":"Galvez-Cancino","year":"2025","journal-title":"Immunity"},{"key":"2026101509311866700_bib78","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s40425-019-0511-6","article-title":"Cancer-cell-secreted CXCL11 promoted CD8+ T cells infiltration through docetaxel-induced-release of HMGB1 in NSCLC","volume":"7","author":"Gao","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"2026101509311866700_bib79","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/S1470-2045(23)00411-4","article-title":"Safety and antitumour activity of cadonilimab, an anti-PD-1\/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): A multicentre, open-label, phase 1b\/2 trial","volume":"24","author":"Gao","year":"2023","journal-title":"Lancet Oncol."},{"key":"2026101509311866700_bib80","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1158\/0008-5472.CAN-23-2812","article-title":"Targeting TACC3 induces immunogenic cell death and enhances T-DM1 response in HER2-positive breast cancer","volume":"84","author":"Gedik","year":"2024","journal-title":"Cancer Res."},{"key":"2026101509311866700_bib81","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/nature24673","article-title":"Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth","volume":"552","author":"Germano","year":"2017","journal-title":"Nature"},{"key":"2026101509311866700_bib82","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1158\/2159-8290.CD-20-0987","article-title":"CD4 T cell-dependent rejection of beta-2 microglobulin null mismatch repair-deficient tumors","volume":"11","author":"Germano","year":"2021","journal-title":"Cancer Discov."},{"key":"2026101509311866700_bib83","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1038\/s43018-025-01070-6","article-title":"Retargeted oncolytic viruses engineered to remodel the tumor microenvironment for glioblastoma immunotherapy","volume":"6","author":"Giovannoni","year":"2025","journal-title":"Nat. Cancer"},{"key":"2026101509311866700_bib84","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1158\/2326-6066.CIR-24-0421","article-title":"The spatial organization of cDC1 with CD8+ T cells is critical for the response to immune checkpoint inhibitors in patients with melanoma","volume":"13","author":"Gobbini","year":"2025","journal-title":"Cancer Immunol. Res."},{"key":"2026101509311866700_bib85","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/s41571-024-00905-y","article-title":"Bispecific and multispecific antibodies in oncology: Opportunities and challenges","volume":"21","author":"Goebeler","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2026101509311866700_bib86","doi-asserted-by":"publisher","first-page":"103716","DOI":"10.1016\/j.dnarep.2024.103716","article-title":"DNA-PK: A synopsis beyond synapsis","volume":"141","author":"Goff","year":"2024","journal-title":"DNA Repair (Amst)"},{"key":"2026101509311866700_bib87","doi-asserted-by":"publisher","first-page":"701968","DOI":"10.3389\/fonc.2021.701968","article-title":"Enhanced antitumor response to immune checkpoint blockade exerted by cisplatin-induced mutagenesis in a murine melanoma model","volume":"11","author":"Gorgun","year":"2021","journal-title":"Front. Oncol."},{"key":"2026101509311866700_bib88","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1038\/s41467-025-68018-3","article-title":"Intratumoral delivery of FLT3L with CXCR3\/CCR5 ligands promotes XCR1+ cDC1 infiltration and activates anti-tumor immunity","volume":"17","author":"Gorline","year":"2025","journal-title":"Nat. Commun."},{"key":"2026101509311866700_bib89","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-012427","article-title":"Characterization of aberrant alternative splicing landscape in patients with metastatic renal cell carcinoma","volume":"14","author":"Govindarajan","year":"2026","journal-title":"J. Immunother. Cancer"},{"key":"2026101509311866700_bib90","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/s41586-025-09655-y","article-title":"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade","volume":"647","author":"Grippin","year":"2025","journal-title":"Nature"},{"key":"2026101509311866700_bib91","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1038\/s41590-022-01291-2","article-title":"Eosinophil-lymphocyte interactions in the tumor microenvironment and cancer immunotherapy","volume":"23","author":"Grisaru-Tal","year":"2022","journal-title":"Nat. Immunol."},{"key":"2026101509311866700_bib92","doi-asserted-by":"publisher","first-page":"3113","DOI":"10.1038\/s41467-026-69703-7","article-title":"B7-H3-mediated cis-inhibition of EGFR by a tumor-selective bispecific antibody enhances anti-tumor efficacy and minimizes toxicities","volume":"17","author":"Guan","year":"2026","journal-title":"Nat. Commun."},{"key":"2026101509311866700_bib93","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1038\/s41586-024-07121-9","article-title":"Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells","volume":"627","author":"Guan","year":"2024","journal-title":"Nature"},{"key":"2026101509311866700_bib94","doi-asserted-by":"publisher","first-page":"8592","DOI":"10.1038\/s41467-024-52577-y","article-title":"Tumor draining lymph nodes connected to cold triple-negative breast cancers are characterized by Th2-associated microenvironment","volume":"15","author":"Guo","year":"2024","journal-title":"Nat. Commun."},{"key":"2026101509311866700_bib95","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-013991","article-title":"Advancing ICOS agonism in solid tumors: Lessons from INDUCE-1","volume":"14","author":"Habibzadeh","year":"2026","journal-title":"J. Immunother. Cancer"},{"key":"2026101509311866700_bib96","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s44341-024-00002-2","article-title":"Hybrid model of tumor growth, angiogenesis and immune response yields strategies to improve antiangiogenic therapy","volume":"1","author":"Hadjigeorgiou","year":"2024","journal-title":"Npj Biol. Phys. Mech."},{"key":"2026101509311866700_bib97","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.ccell.2016.03.005","article-title":"Tumoral immune cell exploitation in colorectal cancer metastases can Be targeted effectively by anti-CCR5 therapy in cancer patients","volume":"29","author":"Halama","year":"2016","journal-title":"Cancer Cell"},{"key":"2026101509311866700_bib98","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.174675","article-title":"Oxygen-carrying nanoemulsions and respiratory hyperoxia eliminate tumor hypoxia-induced immunosuppression","volume":"10","author":"Halpin-Veszeleiova","year":"2025","journal-title":"JCI Insight"},{"key":"2026101509311866700_bib99","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1056\/NEJMoa1305133","article-title":"Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma","volume":"369","author":"Hamid","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"2026101509311866700_bib100","doi-asserted-by":"publisher","first-page":"3400","DOI":"10.1158\/1078-0432.CCR-24-3630","article-title":"Phase I and II clinical studies of the STING agonist ulevostinag with and without pembrolizumab in participants with advanced or metastatic solid tumors or lymphomas","volume":"31","author":"Harrington","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"2026101509311866700_bib101","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.immuni.2019.12.011","article-title":"Top 10 challenges in cancer immunotherapy","volume":"52","author":"Hegde","year":"2020","journal-title":"Immunity"},{"key":"2026101509311866700_bib102","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1038\/s43018-025-01018-w","article-title":"Combination of pembrolizumab and radiotherapy induces systemic antitumor immune responses in immunologically cold non-small cell lung cancer","volume":"6","author":"Huang","year":"2025","journal-title":"Nat. Cancer"},{"key":"2026101509311866700_bib103","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.174027","article-title":"CD4 T cell-activating neoantigens enhance personalized cancer vaccine efficacy","volume":"8","author":"Huff","year":"2023","journal-title":"JCI Insight"},{"key":"2026101509311866700_bib104","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.1038\/s41591-026-04533-0","article-title":"Englumafusp alfa plus glofitamab in B cell non-hodgkin lymphoma: A phase 1 trial","volume":"32","author":"Hutchings","year":"2026","journal-title":"Nat. Med."},{"key":"2026101509311866700_bib105","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/s41591-026-04241-9","article-title":"Clinical development of cancer vaccines","volume":"32","author":"Haanen","year":"2026","journal-title":"Nat. Med."},{"key":"2026101509311866700_bib106","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nature07317","article-title":"STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling","volume":"455","author":"Ishikawa","year":"2008","journal-title":"Nature"},{"key":"2026101509311866700_bib107","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.ijrobp.2022.12.018","article-title":"Proton FLASH radiation therapy and immune infiltration: Evaluation in an orthotopic glioma Rat model","volume":"116","author":"Iturri","year":"2023","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"2026101509311866700_bib108","doi-asserted-by":"publisher","first-page":"812916","DOI":"10.3389\/fonc.2021.812916","article-title":"Interactions between anti-angiogenic therapy and immunotherapy in glioblastoma","volume":"11","author":"Jain","year":"2021","journal-title":"Front. Oncol."},{"key":"2026101509311866700_bib109","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-26-0403","article-title":"Deconvolving SARS-CoV-2 mRNA vaccine impact on immunotherapy-related survival","author":"Jee","year":"2026","journal-title":"Cancer Discov."},{"key":"2026101509311866700_bib110","doi-asserted-by":"publisher","first-page":"1854253","DOI":"10.3389\/fonc.2026.1854253","article-title":"CTSG-expressing mast cells confer resistance to immunotherapy in colorectal cancer","volume":"16","author":"Jiang","year":"2026","journal-title":"Front. Oncol."},{"key":"2026101509311866700_bib111","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1038\/s41571-025-01054-6","article-title":"Therapeutic targeting of mismatch repair-deficient cancers","volume":"22","author":"Johannet","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2026101509311866700_bib112","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1038\/ni.3836","article-title":"De novo induction of intratumoral lymphoid structures and vessel normalization enhances immunotherapy in resistant tumors","volume":"18","author":"Johansson-Percival","year":"2017","journal-title":"Nat. Immunol."},{"key":"2026101509311866700_bib113","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.immuni.2024.01.010","article-title":"LAG-3, TIM-3, and TIGIT: Distinct functions in immune regulation","volume":"57","author":"Joller","year":"2024","journal-title":"Immunity"},{"key":"2026101509311866700_bib114","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1126\/science.aaa6204","article-title":"T cell exclusion, immune privilege, and the tumor microenvironment","volume":"348","author":"Joyce","year":"2015","journal-title":"Science"},{"key":"2026101509311866700_bib115","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1002\/bit.20883","article-title":"Salmonella typhimurium specifically chemotax and proliferate in heterogeneous tumor tissue in vitro","volume":"94","author":"Kasinskas","year":"2006","journal-title":"Biotechnol. Bioeng."},{"key":"2026101509311866700_bib116","doi-asserted-by":"publisher","first-page":"3201","DOI":"10.1158\/0008-5472.CAN-06-2618","article-title":"Salmonella typhimurium lacking ribose chemoreceptors localize in tumor quiescence and induce apoptosis","volume":"67","author":"Kasinskas","year":"2007","journal-title":"Cancer Res."},{"key":"2026101509311866700_bib117","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.36967","article-title":"Topography of cancer-associated immune cells in human solid tumors","volume":"7","author":"Kather","year":"2018","journal-title":"Elife"},{"key":"2026101509311866700_bib118","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/S1470-2045(16)30364-3","article-title":"Avelumab in patients with chemotherapy-refractory metastatic merkel cell carcinoma: A multicentre, single-group, open-label, phase 2 trial","volume":"17","author":"Kaufman","year":"2016","journal-title":"Lancet Oncol."},{"key":"2026101509311866700_bib119","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1158\/2159-8290.CD-23-0964","article-title":"Xaluritamig, a STEAP1 \u00d7 CD3 XmAb 2+1 immune therapy for metastatic castration-resistant prostate cancer: Results from dose exploration in a first-in-human study","volume":"14","author":"Kelly","year":"2024","journal-title":"Cancer Discov."},{"key":"2026101509311866700_bib120","doi-asserted-by":"publisher","first-page":"2533488","DOI":"10.1080\/2162402X.2025.2533488","article-title":"Immunogenic cell death and bystander killing: Expanding the therapeutic potential of modern antibody-drug conjugates","volume":"14","author":"Kepp","year":"2025","journal-title":"Oncoimmunology"},{"key":"2026101509311866700_bib121","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/s41467-017-00729-8","article-title":"Bacterial outer membrane vesicles suppress tumor by interferon-\u03b3-mediated antitumor response","volume":"8","author":"Kim","year":"2017","journal-title":"Nat. Commun."},{"key":"2026101509311866700_bib122","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/nbt.2459","article-title":"Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells","volume":"31","author":"Kloss","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"2026101509311866700_bib123","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.1016\/j.immuni.2026.07.002","article-title":"CCR7+ activated dendritic cells are essential for spontaneous and immunotherapy-driven anti-tumor immunity","volume":"59","author":"Koufaki","year":"2026","journal-title":"Immunity"},{"key":"2026101509311866700_bib124","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1084\/jem.182.2.459","article-title":"CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation","volume":"182","author":"Krummel","year":"1995","journal-title":"J. Exp. Med."},{"key":"2026101509311866700_bib125","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1146\/annurev-genet-112414-054722","article-title":"Eukaryotic mismatch repair in relation to DNA replication","volume":"49","author":"Kunkel","year":"2015","journal-title":"Annu. Rev. Genet."},{"key":"2026101509311866700_bib126","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1038\/s41571-024-00886-y","article-title":"Antiangiogenic-immune-checkpoint inhibitor combinations: Lessons from phase III clinical trials","volume":"21","author":"Kuo","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2026101509311866700_bib127","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41586-024-08552-0","article-title":"Tumour-wide RNA splicing aberrations generate actionable public neoantigens","volume":"639","author":"Kwok","year":"2025","journal-title":"Nature"},{"key":"2026101509311866700_bib128","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/s41571-024-00908-9","article-title":"Exploiting bacteria for cancer immunotherapy","volume":"21","author":"Kwon","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2026101509311866700_bib129","doi-asserted-by":"publisher","first-page":"2857","DOI":"10.3389\/fimmu.2019.02857","article-title":"Local irradiation sensitized tumors to adoptive T cell therapy via enhancing the cross-priming, homing, and cytotoxicity of antigen-specific CD8 T cells","volume":"10","author":"Lai","year":"2019","journal-title":"Front. Immunol."},{"key":"2026101509311866700_bib130","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41523-025-00889-7","article-title":"Agonistic CD40 elicits CD8+ T-cell-dependent primary responses and CD4+ T-cell-dependent long-term immunity in breast cancer","volume":"12","author":"Lam","year":"2026","journal-title":"NPJ Breast Cancer"},{"key":"2026101509311866700_bib131","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1006\/anae.1998.0161","article-title":"Colonisation of Clostridium in the body is restricted to hypoxic and necrotic areas of tumours","volume":"4","author":"Lambin","year":"1998","journal-title":"Anaerobe"},{"key":"2026101509311866700_bib132","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.3324\/haematol.2020.278166","article-title":"Increments in DNA-thioguanine level during thiopurine-enhanced maintenance therapy of acute lymphoblastic leukemia","volume":"106","author":"Larsen","year":"2021","journal-title":"Haematologica"},{"key":"2026101509311866700_bib133","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/s43018-022-00411-z","article-title":"Cancer-associated fibroblasts in the single-cell era","volume":"3","author":"Lavie","year":"2022","journal-title":"Nat. Cancer"},{"key":"2026101509311866700_bib134","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"2026101509311866700_bib135","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41392-025-02249-0","article-title":"Vascular endothelial growth factor signaling in health and disease: From molecular mechanisms to therapeutic perspectives","volume":"10","author":"Lee","year":"2025","journal-title":"Signal Transduct. Target.Ther."},{"key":"2026101509311866700_bib136","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/s41568-019-0106-z","article-title":"Immune control by amino acid catabolism during tumorigenesis and therapy","volume":"19","author":"Lemos","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"2026101509311866700_bib137","doi-asserted-by":"publisher","first-page":"4725","DOI":"10.1038\/s41388-021-01846-x","article-title":"Targeting HIF-1 alpha transcriptional activity drives cytotoxic immune effector cells into melanoma and improves combination immunotherapy","volume":"40","author":"Lequeux","year":"2021","journal-title":"Oncogene"},{"key":"2026101509311866700_bib138","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/s41568-024-00778-4","article-title":"Conventional chemotherapy: Millions of cures, unresolved therapeutic index","volume":"25","author":"Letai","year":"2025","journal-title":"Nat. Rev. Cancer"},{"key":"2026101509311866700_bib139","doi-asserted-by":"publisher","DOI":"10.1172\/JCI138740","article-title":"Radiotherapy-exposed CD8+ and CD4+ neoantigens enhance tumor control","volume":"131","author":"Lhuillier","year":"2021","journal-title":"J. Clin. Invest."},{"key":"2026101509311866700_bib140","doi-asserted-by":"publisher","first-page":"176","DOI":"10.3892\/ol.2020.12037","article-title":"Characteristics and clinical trial results of agonistic anti-CD40 antibodies in the treatment of malignancies","volume":"20","author":"Li","year":"2020","journal-title":"Oncol. Lett."},{"key":"2026101509311866700_bib328","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1126\/science.ade0156","article-title":"Multidimensional control of therapeutic human cell function with synthetic gene circuits","volume":"378","author":"Li","year":"2022","journal-title":"Science"},{"key":"2026101509311866700_bib141","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1038\/s41419-026-08607-2","article-title":"The cGAS-STING pathway in cancer: Friend or foe","volume":"17","author":"Li","year":"2026","journal-title":"Cell Death Dis."},{"key":"2026101509311866700_bib142","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s40364-026-00949-5","article-title":"Roles of neutrophil extracellular traps in cancer immunotherapy resistance and therapeutic targeting","volume":"14","author":"Li","year":"2026","journal-title":"Biomark Res."},{"key":"2026101509311866700_bib144","doi-asserted-by":"publisher","first-page":"700407","DOI":"10.3389\/fonc.2021.700407","article-title":"Targeting hypoxia: Hypoxia-activated prodrugs in cancer therapy","volume":"11","author":"Li","year":"2021","journal-title":"Front. Oncol."},{"key":"2026101509311866700_bib145","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/s41392-023-01407-6","article-title":"Oncolytic virotherapy: Basic principles, recent advances and future directions","volume":"8","author":"Lin","year":"2023","journal-title":"Signal. Transduct. Target. Ther."},{"key":"2026101509311866700_bib146","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa2312948","article-title":"Blinatumomab for MRD-negative acute lymphoblastic leukemia in adults","volume":"391","author":"Litzow","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"2026101509311866700_bib147","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/s41568-023-00586-2","article-title":"mRNA-based cancer therapeutics","volume":"23","author":"Liu","year":"2023","journal-title":"Nat. Rev. Cancer"},{"key":"2026101509311866700_bib148","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/s41590-023-01430-3","article-title":"CD40 signal rewires fatty acid and glutamine metabolism for stimulating macrophage anti-tumorigenic functions","volume":"24","author":"Liu","year":"2023","journal-title":"Nat. Immunol."},{"key":"2026101509311866700_bib149","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41419-023-06211-2","article-title":"Radiotherapy remodels the tumor microenvironment for enhancing immunotherapeutic sensitivity","volume":"14","author":"Liu","year":"2023","journal-title":"Cell Death Dis."},{"key":"2026101509311866700_bib150","doi-asserted-by":"publisher","first-page":"1698158","DOI":"10.3389\/fimmu.2025.1698158","article-title":"Synthetic biology approaches to enhance cancer immune responses","volume":"16","author":"Liu","year":"2025","journal-title":"Front. Immunol."},{"key":"2026101509311866700_bib151","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41420-026-03012-2","article-title":"Integration of immunogenic cell death in the treatment landscape of non-small cell lung cancer: Harnessing the power of the immune system","volume":"12","author":"Liu","year":"2026","journal-title":"Cell Death Discov."},{"key":"2026101509311866700_bib152","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/S1470-2045(19)30274-8","article-title":"Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301\/KEYNOTE-252): A phase 3, randomised, double-blind study","volume":"20","author":"Long","year":"2019","journal-title":"Lancet Oncol."},{"key":"2026101509311866700_bib153","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200987","article-title":"Conventional type-1 DC density is associated with checkpoint inhibitor response across multiple types of cancer","volume":"136","author":"Lopez-Janeiro","year":"2026","journal-title":"J. Clin. Invest."},{"key":"2026101509311866700_bib154","doi-asserted-by":"publisher","first-page":"e450","DOI":"10.1016\/S1470-2045(22)00372-2","article-title":"Clinical advances and ongoing trials on mRNA vaccines for cancer treatment","volume":"23","author":"Lorentzen","year":"2022","journal-title":"Lancet Oncol."},{"key":"2026101509311866700_bib155","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1038\/s41577-024-01061-1","article-title":"CD28 co-stimulation: Novel insights and applications in cancer immunotherapy","volume":"24","author":"Lotze","year":"2024","journal-title":"Nat. Rev. Immunol."},{"key":"2026101509311866700_bib156","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1158\/1078-0432.CCR-24-2824","article-title":"Intratumoral or subcutaneous MK-2118, a noncyclic dinucleotide STING agonist, with or without pembrolizumab, for advanced or metastatic solid tumors or lymphomas","volume":"31","author":"Luke","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"2026101509311866700_bib157","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13046-025-03279-w","article-title":"Targeting RNA splicing modulation: New perspectives for anticancer strategy?","volume":"44","author":"Lv","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2026101509311866700_bib158","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.actbio.2025.02.012","article-title":"Proteolysis-targeting chimera-doxorubicin conjugate nanoassemblies for dual treatment of EGFR-TKI sensitive and resistant non-small cell lung cancer","volume":"195","author":"Ma","year":"2025","journal-title":"Acta Biomater."},{"key":"2026101509311866700_bib159","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1158\/2767-9764.CRC-24-0278","article-title":"A precision engineered interleukin-2 for bolstering CD8+ T- and NK-cell activity without eosinophilia and vascular leak syndrome in nonhuman primates","volume":"4","author":"Ma","year":"2024","journal-title":"Cancer Res. Commun."},{"key":"2026101509311866700_bib160","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.it.2022.08.004","article-title":"Harnessing IL-15 signaling to potentiate NK cell-mediated cancer immunotherapy","volume":"43","author":"Ma","year":"2022","journal-title":"Trends Immunol."},{"key":"2026101509311866700_bib161","doi-asserted-by":"publisher","first-page":"4118","DOI":"10.1038\/s41467-022-31764-9","article-title":"Hypoxia induces HIF1\u03b1-dependent epigenetic vulnerability in triple negative breast cancer to confer immune effector dysfunction and resistance to anti-PD-1 immunotherapy","volume":"13","author":"Ma","year":"2022","journal-title":"Nat. Commun."},{"key":"2026101509311866700_bib162","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1126\/science.abc3421","article-title":"Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy","volume":"369","author":"Mager","year":"2020","journal-title":"Science"},{"key":"2026101509311866700_bib163","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1158\/2326-6066.CIR-24-0298","article-title":"NI-3201 is a bispecific antibody mediating PD-L1-dependent CD28 Co-stimulation on T cells for enhanced tumor control","volume":"13","author":"Majocchi","year":"2025","journal-title":"Cancer Immunol. Res."},{"key":"2026101509311866700_bib164","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s40425-018-0399-6","article-title":"Resident memory T cells, critical components in tumor immunology","volume":"6","author":"Mami-Chouaib","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"2026101509311866700_bib165","doi-asserted-by":"publisher","first-page":"114336","DOI":"10.1016\/j.ejca.2024.114336","article-title":"Duration of immunotherapy in dMMR\/MSI-H metastatic colorectal cancer patients","volume":"212","author":"Margalit","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"2026101509311866700_bib166","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41540-023-00327-z","article-title":"Exploring chronic and transient tumor hypoxia for predicting the efficacy of hypoxia-activated pro-drugs","volume":"10","author":"Mathur","year":"2024","journal-title":"Npj Syst. Biol. Appl."},{"key":"2026101509311866700_bib167","doi-asserted-by":"publisher","DOI":"10.1126\/science.ady1678","article-title":"Dendritic cells control tertiary lymphoid structure development and maintenance in cancer","volume":"393","author":"Mattiuz","year":"2026","journal-title":"Science"},{"key":"2026101509311866700_bib168","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1126\/science.aaf1490","article-title":"Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade","volume":"351","author":"McGranahan","year":"2016","journal-title":"Science"},{"key":"2026101509311866700_bib169","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41568-020-0246-1","article-title":"Inflammatory microenvironment remodelling by tumour cells after radiotherapy","volume":"20","author":"McLaughlin","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"2026101509311866700_bib170","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1158\/1078-0432.CCR-24-1660","article-title":"Facts and hopes of CD40 agonists in cancer immunotherapy","volume":"31","author":"McVey","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"2026101509311866700_bib171","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1038\/s41586-024-08305-z","article-title":"Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours","volume":"637","author":"Melero","year":"2025","journal-title":"Nature"},{"key":"2026101509311866700_bib172","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1038\/s41591-026-04380-z","article-title":"Cibisatamab and FAP-4-1BBL in microsatellite-stable colorectal cancer: A phase 1b trial","volume":"32","author":"Melero","year":"2026","journal-title":"Nat. Med."},{"key":"2026101509311866700_bib173","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/nrc2373","article-title":"Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines","volume":"8","author":"Melief","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"2026101509311866700_bib174","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1016\/j.immuni.2023.09.011","article-title":"The cancer-immunity cycle: Indication, genotype, and immunotype","volume":"56","author":"Mellman","year":"2023","journal-title":"Immunity"},{"key":"2026101509311866700_bib175","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41568-023-00635-w","article-title":"How chemokines organize the tumour microenvironment","volume":"24","author":"Mempel","year":"2024","journal-title":"Nat. Rev. Cancer"},{"key":"2026101509311866700_bib176","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1158\/1078-0432.CCR-22-2235","article-title":"Combination of the STING agonist MIW815 (ADU-S100) and PD-1 inhibitor spartalizumab in advanced\/metastatic solid tumors or lymphomas: An open-label, multicenter, phase Ib study","volume":"29","author":"Meric-Bernstam","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"2026101509311866700_bib177","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s41467-023-44308-6","article-title":"T-cell stimulating vaccines empower CD3 bispecific antibody therapy in solid tumors","volume":"15","author":"Middelburg","year":"2024","journal-title":"Nat. Commun."},{"key":"2026101509311866700_bib178","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/nrmicro777","article-title":"Clostridia in cancer therapy","volume":"1","author":"Minton","year":"2003","journal-title":"Nat. Rev. Microbiol."},{"key":"2026101509311866700_bib179","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.annonc.2020.06.004","article-title":"The forefront of ovarian cancer therapy: Update on PARP inhibitors","volume":"31","author":"Mirza","year":"2020","journal-title":"Ann. Oncol."},{"key":"2026101509311866700_bib180","doi-asserted-by":"publisher","first-page":"17117","DOI":"10.1038\/nmicrobiol.2017.117","article-title":"Translational fidelity and mistranslation in the cellular response to stress","volume":"2","author":"Mohler","year":"2017","journal-title":"Nat. Microbiol."},{"key":"2026101509311866700_bib181","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1093\/jnci\/djab169","article-title":"Homologous recombination deficiency alterations in colorectal cancer: Clinical, molecular, and prognostic implications","volume":"114","author":"Moretto","year":"2022","journal-title":"J. Natl. Cancer Inst."},{"key":"2026101509311866700_bib182","doi-asserted-by":"publisher","first-page":"e152","DOI":"10.1016\/S1470-2045(24)00656-9","article-title":"Proceedings of the National Cancer Institute Workshop on combining immunotherapy with radiotherapy: Challenges and opportunities for clinical translation","volume":"26","author":"Morris","year":"2025","journal-title":"Lancet Oncol."},{"key":"2026101509311866700_bib183","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"2026101509311866700_bib184","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1056\/NEJMoa2502099","article-title":"Tarlatamab in small-cell lung cancer after platinum-based chemotherapy","volume":"393","author":"Mountzios","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"2026101509311866700_bib185","doi-asserted-by":"publisher","first-page":"100990","DOI":"10.1016\/j.neo.2024.100990","article-title":"A synergistic approach for modulating the tumor microenvironment to enhance nano-immunotherapy in sarcomas","volume":"51","author":"Mpekris","year":"2024","journal-title":"Neoplasia"},{"key":"2026101509311866700_bib186","doi-asserted-by":"publisher","first-page":"101626","DOI":"10.1016\/j.xcrm.2024.101626","article-title":"Modulating cancer mechanopathology to restore vascular function and enhance immunotherapy","volume":"5","author":"Mpekris","year":"2024","journal-title":"Cell Rep. Med."},{"key":"2026101509311866700_bib187","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-011905","article-title":"ANV600 is a novel PD-1 targeted IL-2R\u03b2\u03b3 agonist that selectively expands tumor antigen-specific T cells and potentiates PD-1 checkpoint inhibitor therapy","volume":"13","author":"Murer","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"2026101509311866700_bib188","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41586-025-09913-z","article-title":"Microbiota-induced T cell plasticity enables immune-mediated tumour control","volume":"651","author":"Najar","year":"2026","journal-title":"Nature"},{"key":"2026101509311866700_bib189","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","article-title":"Overall survival benefit with tebentafusp in metastatic uveal melanoma","volume":"385","author":"Nathan","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"2026101509311866700_bib190","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1146\/annurev-med-043024-123559","article-title":"Regulatory T cell depletion in cancer: Challenges, opportunities, and future directions for antibody development","volume":"77","author":"Navarrete","year":"2026","journal-title":"Annu. Rev. Med."},{"key":"2026101509311866700_bib191","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2423246122","article-title":"Thiopurine therapy enhances immune checkpoint inhibitor efficacy in low-mutational burden melanoma: A promising anticancer approach","volume":"122","author":"Nazerai","year":"2025","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2026101509311866700_bib192","doi-asserted-by":"publisher","first-page":"2158610","DOI":"10.1080\/2162402X.2022.2158610","article-title":"Thiopurine 6TG treatment increases tumor immunogenicity and response to immune checkpoint blockade","volume":"12","author":"Nazerai","year":"2023","journal-title":"Oncoimmunology"},{"key":"2026101509311866700_bib193","doi-asserted-by":"publisher","first-page":"3864","DOI":"10.1158\/1078-0432.CCR-24-3952","article-title":"Phase Ib study of pembrolizumab in combination with intratumoral injection of Clostridium novyi-NT in patients with advanced solid tumors","volume":"31","author":"Nelson","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"2026101509311866700_bib194","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1038\/s43018-025-00905-6","article-title":"FLASH radiation reprograms lipid metabolism and macrophage immunity and sensitizes medulloblastoma to CAR-T cell therapy","volume":"6","author":"Ni","year":"2025","journal-title":"Nat. Cancer"},{"key":"2026101509311866700_bib195","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1038\/s41551-022-00966-3","article-title":"Author Correction: Synergistic checkpoint-blockade and radiotherapy-radiodynamic therapy via an immunomodulatory nanoscale metal-organic framework","volume":"6","author":"Ni","year":"2022","journal-title":"Nat. Biomed. Eng."},{"key":"2026101509311866700_bib196","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41551-022-00846-w","article-title":"Synergistic checkpoint-blockade and radiotherapy-radiodynamic therapy via an immunomodulatory nanoscale metal-organic framework","volume":"6","author":"Ni","year":"2022","journal-title":"Nat. Biomed. Eng."},{"key":"2026101509311866700_bib197","doi-asserted-by":"publisher","DOI":"10.1172\/JCI180278","article-title":"DNA-PK inhibition enhances neoantigen diversity and increases T cell responses to immunoresistant tumors","volume":"134","author":"Nielsen","year":"2024","journal-title":"J. Clin. Invest."},{"key":"2026101509311866700_bib198","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/s41591-022-02163-w","article-title":"Persistent mutation burden drives sustained anti-tumor immune responses","volume":"29","author":"Niknafs","year":"2023","journal-title":"Nat. Med."},{"key":"2026101509311866700_bib199","doi-asserted-by":"publisher","first-page":"1433679","DOI":"10.3389\/fimmu.2024.1433679","article-title":"Efficacy and safety evaluation of cross-reactive Fibroblast activation protein scFv-based CAR-T cells","volume":"15","author":"Niu","year":"2024","journal-title":"Front. Immunol."},{"key":"2026101509311866700_bib200","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1038\/s43018-024-00870-6","article-title":"TIGIT and PD-L1 co-blockade promotes clonal expansion of multipotent, non-exhausted antitumor T cells by facilitating co-stimulation","volume":"5","author":"Nutsch","year":"2024","journal-title":"Nat. Cancer"},{"key":"2026101509311866700_bib201","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(23)02405-4","article-title":"Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): A randomised, open-label, phase 3 trial","volume":"403","author":"Oaknin","year":"2024","journal-title":"Lancet"},{"key":"2026101509311866700_bib202","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1038\/ni.2762","article-title":"A rheostat for immune responses: The unique properties of PD-1 and their advantages for clinical application","volume":"14","author":"Okazaki","year":"2013","journal-title":"Nat. Immunol."},{"key":"2026101509311866700_bib203","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1016\/j.ccell.2025.07.013","article-title":"Fc-optimized CD40 agonistic antibody elicits tertiary lymphoid structure formation and systemic antitumor immunity in metastatic cancer","volume":"43","author":"Osorio","year":"2025","journal-title":"Cancer Cell"},{"key":"2026101509311866700_bib204","doi-asserted-by":"publisher","first-page":"4983","DOI":"10.1158\/1078-0432.CCR-19-4092","article-title":"Radiation with STAT3 blockade triggers dendritic cell-T cell interactions in the glioma microenvironment and therapeutic efficacy","volume":"26","author":"Ott","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"2026101509311866700_bib205","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.cell.2020.08.053","article-title":"A phase Ib trial of personalized neoantigen therapy plus anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer","volume":"183","author":"Ott","year":"2020","journal-title":"Cell"},{"key":"2026101509311866700_bib206","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1038\/s41591-022-01829-9","article-title":"Sotigalimab and\/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: Clinical and immunologic analyses from the randomized phase 2 PRINCE trial","volume":"28","author":"Padr\u00f3n","year":"2022","journal-title":"Nat. Med."},{"key":"2026101509311866700_bib207","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41591-023-02760-3","article-title":"Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: The phase 1 AMPLIFY-201 trial","volume":"30","author":"Pant","year":"2024","journal-title":"Nat. Med."},{"key":"2026101509311866700_bib208","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-012288","article-title":"Genetic drivers of tumor microenvironment and immunotherapy resistance in non-small cell lung cancer: The role of KEAP1, SMARCA4, and PTEN mutations","volume":"13","author":"Paredes","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"2026101509311866700_bib209","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/nature08999","article-title":"Induction of tumour immunity by targeted inhibition of nonsense-mediated mRNA decay","volume":"465","author":"Pastor","year":"2010","journal-title":"Nature"},{"key":"2026101509311866700_bib210","doi-asserted-by":"publisher","first-page":"6923","DOI":"10.1038\/s41467-024-51236-6","article-title":"Sculpting the tumour microenvironment by combining radiotherapy and ATR inhibition for curative-intent adjuvant immunotherapy","volume":"15","author":"Patin","year":"2024","journal-title":"Nat. Commun."},{"key":"2026101509311866700_bib211","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1172\/JCI32205","article-title":"Microbial translocation augments the function of adoptively transferred self\/tumor-specific CD8+ T cells via TLR4 signaling","volume":"117","author":"Paulos","year":"2007","journal-title":"J. Clin. Invest."},{"key":"2026101509311866700_bib212","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.ccell.2023.04.001","article-title":"Simultaneous targeting of PD-1 and IL-2R\u03b2\u03b3 with radiation therapy inhibits pancreatic cancer growth and metastasis","volume":"41","author":"Piper","year":"2023","journal-title":"Cancer Cell"},{"key":"2026101509311866700_bib213","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1008866","article-title":"Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy","volume":"4","author":"Pol","year":"2015","journal-title":"Oncoimmunology"},{"key":"2026101509311866700_bib214","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005301","article-title":"First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1)","volume":"11","author":"Postel-Vinay","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"2026101509311866700_bib215","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1038\/nri2163","article-title":"IDO and regulatory T cells: A role for reverse signalling and non-canonical NF-kappaB activation","volume":"7","author":"Puccetti","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"2026101509311866700_bib216","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1038\/s41551-025-01380-1","article-title":"Sensitization of tumours to immunotherapy by boosting early type-I interferon responses enables epitope spreading","volume":"9","author":"Qdaisat","year":"2025","journal-title":"Nat. Biomed. Eng."},{"key":"2026101509311866700_bib217","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1016\/S1470-2045(25)00543-1","article-title":"Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): Final analysis of a randomised, open-label, international, phase 3 study","volume":"26","author":"Qin","year":"2025","journal-title":"Lancet Oncol."},{"key":"2026101509311866700_bib218","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1038\/s41591-024-03449-x","article-title":"Donor-derived GD2-specific CAR T cells in relapsed or refractory neuroblastoma","volume":"31","author":"Quintarelli","year":"2025","journal-title":"Nat. Med."},{"key":"2026101509311866700_bib219","doi-asserted-by":"publisher","first-page":"1503018","DOI":"10.3389\/fimmu.2024.1503018","article-title":"CD28 shapes T cell receptor signaling by regulating Lck dynamics and ZAP70 activation","volume":"15","author":"Raychaudhuri","year":"2024","journal-title":"Front. Immunol."},{"key":"2026101509311866700_bib220","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1084\/jem.20052494","article-title":"Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy","volume":"203","author":"Reits","year":"2006","journal-title":"J. Exp. Med."},{"key":"2026101509311866700_bib221","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/S1470-2045(21)00252-7","article-title":"Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): A randomised, open-label, phase 2-3 study","volume":"22","author":"Ren","year":"2021","journal-title":"Lancet Oncol."},{"key":"2026101509311866700_bib222","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus Axitinib versus Sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"2026101509311866700_bib223","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): A phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet"},{"key":"2026101509311866700_bib224","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"2026101509311866700_bib225","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"2026101509311866700_bib226","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"2026101509311866700_bib227","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","article-title":"Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer","volume":"618","author":"Rojas","year":"2023","journal-title":"Nature"},{"key":"2026101509311866700_bib228","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"key":"2026101509311866700_bib229","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1016\/j.ccell.2025.05.010","article-title":"Induction of a mismatch repair deficient genotype by tailored chemical mutagenesis in experimental models of cancer","volume":"43","author":"Rousseau","year":"2025","journal-title":"Cancer Cell"},{"key":"2026101509311866700_bib230","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.aan3706","article-title":"Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors","volume":"359","author":"Routy","year":"2018","journal-title":"Science"},{"key":"2026101509311866700_bib231","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.cell.2016.09.011","article-title":"Engineering T cells with customized therapeutic response programs using synthetic notch receptors","volume":"167","author":"Roybal","year":"2016","journal-title":"Cell"},{"key":"2026101509311866700_bib232","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/s41586-020-2537-9","article-title":"An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma","volume":"585","author":"Sahin","year":"2020","journal-title":"Nature"},{"key":"2026101509311866700_bib233","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/nrm3289","article-title":"Y-family DNA polymerases and their role in tolerance of cellular DNA damage","volume":"13","author":"Sale","year":"2012","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2026101509311866700_bib234","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1158\/2159-8290.CD-15-0510","article-title":"Cancer immunotherapy with immunomodulatory anti-CD137 and anti-PD-1 monoclonal antibodies requires BATF3-dependent dendritic cells","volume":"6","author":"S\u00e1nchez-Paulete","year":"2016","journal-title":"Cancer Discov."},{"key":"2026101509311866700_bib235","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/S1470-2045(23)00638-1","article-title":"Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH act): A multicentre, retrospective study","volume":"25","author":"Sathekge","year":"2024","journal-title":"Lancet Oncol."},{"key":"2026101509311866700_bib236","first-page":"A877","article-title":"773 SOF10, selectively blocking latent TGF-\u03b21 activation, potentiates the efficacy of checkpoint blockade therapy by modulating CAF dynamics and T cell infiltration","volume":"12","author":"Sato","year":"2024","journal-title":"J. ImmunoTherapy Cancer"},{"key":"2026101509311866700_bib237","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1056\/NEJMoa2405008","article-title":"Efficacy of zenocutuzumab in NRG1 fusion-positive cancer","volume":"392","author":"Schram","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"2026101509311866700_bib238","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in cancer immunotherapy","volume":"348","author":"Schumacher","year":"2015","journal-title":"Science"},{"key":"2026101509311866700_bib239","doi-asserted-by":"publisher","DOI":"10.1126\/science.abf9419","article-title":"Tertiary lymphoid structures in cancer","volume":"375","author":"Schumacher","year":"2022","journal-title":"Science"},{"key":"2026101509311866700_bib240","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1158\/2159-8290.CD-20-0522","article-title":"Tumor mutational burden as a predictive biomarker in solid tumors","volume":"10","author":"Sha","year":"2020","journal-title":"Cancer Discov."},{"key":"2026101509311866700_bib241","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","article-title":"Immune checkpoint therapy-current perspectives and future directions","volume":"186","author":"Sharma","year":"2023","journal-title":"Cell"},{"key":"2026101509311866700_bib242","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"2026101509311866700_bib243","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41586-025-08717-5","article-title":"Oncolytic virus VG161 in refractory hepatocellular carcinoma","volume":"641","author":"Shen","year":"2025","journal-title":"Nature"},{"key":"2026101509311866700_bib244","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/s41565-025-02102-z","article-title":"Prodrug-tethered lipid nanoparticles for synergistic messenger RNA cancer immunotherapy","volume":"21","author":"Shi","year":"2026","journal-title":"Nat. Nanotechnol."},{"key":"2026101509311866700_bib245","doi-asserted-by":"publisher","first-page":"1549276","DOI":"10.3389\/fimmu.2025.1549276","article-title":"Research progress of HIF-1a on immunotherapy outcomes in immune vascular microenvironment","volume":"16","author":"Shi","year":"2025","journal-title":"Front. Immunol."},{"key":"2026101509311866700_bib246","doi-asserted-by":"publisher","first-page":"1125253","DOI":"10.3389\/fimmu.2023.1125253","article-title":"Self-assembled nanoparticles: A new platform for revolutionizing therapeutic cancer vaccines","volume":"14","author":"Shi","year":"2023","journal-title":"Front. Immunol."},{"key":"2026101509311866700_bib247","doi-asserted-by":"publisher","first-page":"101531","DOI":"10.1016\/j.xcrm.2024.101531","article-title":"Next-generation anti-PD-L1\/IL-15 immunocytokine elicits superior antitumor immunity in cold tumors with minimal toxicity","volume":"5","author":"Shi","year":"2024","journal-title":"Cell Rep. Med."},{"key":"2026101509311866700_bib248","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008594","article-title":"Novel anti-CD73-IL-2v bispecific fusion protein augments antitumor immunity by alleviating immunosuppressive adenosine pathways in CD8+ T cells","volume":"13","author":"Shin","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"2026101509311866700_bib249","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.immuni.2024.02.001","article-title":"Interleukin-2 signaling in the regulation of T cell biology in autoimmunity and cancer","volume":"57","author":"Shouse","year":"2024","journal-title":"Immunity"},{"key":"2026101509311866700_bib250","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/s12943-025-02390-y","article-title":"Bispecific antibodies: Unleashing a new era in oncology treatment","volume":"24","author":"Shui","year":"2025","journal-title":"Mol. Cancer"},{"key":"2026101509311866700_bib251","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/s41571-023-00803-9","article-title":"Towards modulating the gut microbiota to enhance the efficacy of immune-checkpoint inhibitors","volume":"20","author":"Simpson","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2026101509311866700_bib252","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1084\/jem.20130579","article-title":"Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma","volume":"210","author":"Simpson","year":"2013","journal-title":"J. Exp. Med."},{"key":"2026101509311866700_bib253","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1186\/s12885-020-06964-5","article-title":"Damage-associated molecular patterns (DAMPs) related to immunogenic cell death are differentially triggered by clinically relevant chemotherapeutics in lung adenocarcinoma cells","volume":"20","author":"Solari","year":"2020","journal-title":"BMC Cancer"},{"key":"2026101509311866700_bib254","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1038\/s43018-020-00133-0","article-title":"CD25-Treg-depleting antibodies preserving IL-2 signaling on effector T cells enhance effector activation and antitumor immunity","volume":"1","author":"Solomon","year":"2020","journal-title":"Nat. Cancer"},{"key":"2026101509311866700_bib255","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1038\/s41577-018-0046-y","article-title":"Biology and regulation of IL-2: From molecular mechanisms to human therapy","volume":"18","author":"Spolski","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"2026101509311866700_bib256","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nature14404","article-title":"Melanoma-intrinsic \u03b2-catenin signalling prevents anti-tumour immunity","volume":"523","author":"Spranger","year":"2015","journal-title":"Nature"},{"key":"2026101509311866700_bib257","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.ccell.2017.04.003","article-title":"Tumor-residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy","volume":"31","author":"Spranger","year":"2017","journal-title":"Cancer Cell"},{"key":"2026101509311866700_bib258","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/nrc.2017.117","article-title":"Impact of oncogenic pathways on evasion of antitumour immune responses","volume":"18","author":"Spranger","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"2026101509311866700_bib259","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1038\/s43018-026-01150-1","article-title":"Tumor-localized CD40 agonism with MP0317, a FAP x CD40 DARPin, reprograms the tumor microenvironment in patients with advanced solid tumors: An open-label, nonrandomized, dose-escalation phase 1 study","volume":"7","author":"Steeghs","year":"2026","journal-title":"Nat. Cancer"},{"key":"2026101509311866700_bib260","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/nrm2008","article-title":"Mechanism of homologous recombination: Mediators and helicases take on regulatory functions","volume":"7","author":"Sung","year":"2006","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2026101509311866700_bib261","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1126\/science.273.5278.1109","article-title":"Role of postreplicative DNA mismatch repair in the cytotoxic action of thioguanine","volume":"273","author":"Swann","year":"1996","journal-title":"Science"},{"key":"2026101509311866700_bib262","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/s41568-022-00481-2","article-title":"Nonsense-mediated RNA decay: An emerging modulator of malignancy","volume":"22","author":"Tan","year":"2022","journal-title":"Nat. Rev. Cancer"},{"key":"2026101509311866700_bib263","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/j.ijrobp.2026.04.018","article-title":"FLASH radiotherapy mitigates radiation-induced lymphopenia and prevents immunosuppression via Chk1-STAT3 Axis modulation in a preclinical thoracic irradiation model","volume":"126","author":"Tao","year":"2026","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"2026101509311866700_bib264","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"2026101509311866700_bib265","doi-asserted-by":"publisher","first-page":"4373","DOI":"10.1158\/0008-5472.CAN-22-1046","article-title":"Depletion of conventional type-1 dendritic cells in established tumors suppresses immunotherapy efficacy","volume":"82","author":"Teijeira","year":"2022","journal-title":"Cancer Res."},{"key":"2026101509311866700_bib266","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1038\/nature21724","article-title":"Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming","volume":"544","author":"Tian","year":"2017","journal-title":"Nature"},{"key":"2026101509311866700_bib267","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.immuni.2022.12.006","article-title":"Bispecific PD1-IL2v and anti-PD-L1 break tumor immunity resistance by enhancing stem-like tumor-reactive CD8+ T cells and reprogramming macrophages","volume":"56","author":"Tichet","year":"2023","journal-title":"Immunity"},{"key":"2026101509311866700_bib268","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1038\/s41375-022-01591-4","article-title":"Maintenance therapy for acute lymphoblastic leukemia: Basic science and clinical translations","volume":"36","author":"Toksvang","year":"2022","journal-title":"Leukemia"},{"key":"2026101509311866700_bib269","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/j.ccell.2023.07.011","article-title":"Neoadjuvant immune checkpoint blockade: A window of opportunity to advance cancer immunotherapy","volume":"41","author":"Topalian","year":"2023","journal-title":"Cancer Cell"},{"key":"2026101509311866700_bib270","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/s41568-018-0009-4","article-title":"Oncolytic viruses as engineering platforms for combination immunotherapy","volume":"18","author":"Twumasi-Boateng","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"2026101509311866700_bib271","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/nature14292","article-title":"Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer","volume":"520","author":"Twyman-Saint Victor","year":"2015","journal-title":"Nature"},{"key":"2026101509311866700_bib272","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41588-020-00752-4","article-title":"The association between tumor mutational burden and prognosis is dependent on treatment context","volume":"53","author":"Valero","year":"2021","journal-title":"Nat. Genet."},{"key":"2026101509311866700_bib273","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/nri724","article-title":"Epitope spreading in immune-mediated diseases: Implications for immunotherapy","volume":"2","author":"Vanderlugt","year":"2002","journal-title":"Nat. Rev. Immunol."},{"key":"2026101509311866700_bib274","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1038\/s43018-021-00232-6","article-title":"Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression","volume":"2","author":"Vanhersecke","year":"2021","journal-title":"Nat. Cancer"},{"key":"2026101509311866700_bib275","doi-asserted-by":"publisher","first-page":"15618","DOI":"10.1038\/ncomms15618","article-title":"DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity","volume":"8","author":"Vanpouille-Box","year":"2017","journal-title":"Nat. Commun."},{"key":"2026101509311866700_bib276","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1016\/j.immuni.2026.02.005","article-title":"Nonsense-mediated mRNA decay inhibition reshapes the cancer immunopeptidome","volume":"59","author":"Vendramin","year":"2026","journal-title":"Immunity"},{"key":"2026101509311866700_bib277","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/s41590-022-01379-9","article-title":"Hypoxia drives CD39-dependent suppressor function in exhausted T cells to limit antitumor immunity","volume":"24","author":"Vignali","year":"2023","journal-title":"Nat. Immunol."},{"key":"2026101509311866700_bib278","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1016\/j.ccell.2025.05.014","article-title":"Cisplatin and temozolomide combinatorial treatment triggers hypermutability and immune surveillance in experimental cancer models","volume":"43","author":"Vitiello","year":"2025","journal-title":"Cancer Cell"},{"key":"2026101509311866700_bib279","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1146\/annurev-med-062518-045435","article-title":"CD40 agonist antibodies in cancer immunotherapy","volume":"71","author":"Vonderheide","year":"2020","journal-title":"Annu. Rev. Med."},{"key":"2026101509311866700_bib280","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s41568-025-00878-9","article-title":"Mechanisms, challenges and opportunities for FLASH radiotherapy in cancer","volume":"26","author":"Vozenin","year":"2026","journal-title":"Nat. Rev. Cancer"},{"key":"2026101509311866700_bib281","doi-asserted-by":"publisher","first-page":"868","DOI":"10.3389\/fimmu.2020.00868","article-title":"IL-15 in the combination immunotherapy of cancer","volume":"11","author":"Waldmann","year":"2020","journal-title":"Front. Immunol."},{"key":"2026101509311866700_bib282","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-012829","article-title":"Anti-HER2\u00d7CCR4 bispecific antibody enhances antitumor immunity in advanced HER2-positive tumors by chemotaxis blockade and depletion of tumor-associated Tregs, without inducing systemic toxicity","volume":"13","author":"Wang","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"2026101509311866700_bib283","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s12967-025-07645-2","article-title":"Cell-type specific activation of the cGAS-STING pathway in tumor immunotherapy: Mechanisms and therapeutic implications","volume":"24","author":"Wang","year":"2026","journal-title":"J. Transl Med."},{"key":"2026101509311866700_bib284","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.ade5855","article-title":"Therapeutic blocking of VEGF binding to neuropilin-2 diminishes PD-L1 expression to activate antitumor immunity in prostate cancer","volume":"15","author":"Wang","year":"2023","journal-title":"Sci. Transl Med."},{"key":"2026101509311866700_bib285","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1226","article-title":"Therapeutic strategies to remodel immunologically cold tumors","volume":"9","author":"Wang","year":"2020","journal-title":"Clin. Translational Immunol."},{"key":"2026101509311866700_bib286","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12964-023-01063-x","article-title":"Cancer immune evasion through KRAS and PD-L1 and potential therapeutic interventions","volume":"21","author":"Watterson","year":"2023","journal-title":"Cell Commun. Signal."},{"key":"2026101509311866700_bib287","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1146\/annurev-immunol-082423-040557","article-title":"TNF\/TNFR superfamily members in Costimulation of T cell responses-revisited","volume":"43","author":"Watts","year":"2025","journal-title":"Annu. Rev. Immunol."},{"key":"2026101509311866700_bib288","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","article-title":"Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): A randomised, phase 2b study","volume":"403","author":"Weber","year":"2024","journal-title":"Lancet"},{"key":"2026101509311866700_bib289","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental mechanisms of immune checkpoint blockade therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discov."},{"key":"2026101509311866700_bib290","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.ccell.2025.03.003","article-title":"Translation dysregulation in cancer as a source for targetable antigens","volume":"43","author":"Weller","year":"2025","journal-title":"Cancer Cell"},{"key":"2026101509311866700_bib291","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1038\/s41588-023-01499-4","article-title":"Mismatch repair deficiency is not sufficient to elicit tumor immunogenicity","volume":"55","author":"Westcott","year":"2023","journal-title":"Nat. Genet."},{"key":"2026101509311866700_bib292","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1038\/d41586-025-01570-6","article-title":"Cancer-fighting immune cells could soon be engineered inside our bodies","volume":"641","author":"Willyard","year":"2025","journal-title":"Nature"},{"key":"2026101509311866700_bib293","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa2407417","article-title":"Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma","volume":"392","author":"Wolchok","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"2026101509311866700_bib294","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.cell.2019.08.032","article-title":"UVB-induced tumor heterogeneity diminishes immune response in melanoma","volume":"179","author":"Wolf","year":"2019","journal-title":"Cell"},{"key":"2026101509311866700_bib295","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/j.immuni.2014.10.017","article-title":"STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors","volume":"41","author":"Woo","year":"2014","journal-title":"Immunity"},{"key":"2026101509311866700_bib296","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41392-024-01979-x","article-title":"Cold and hot tumors: From molecular mechanisms to targeted therapy","volume":"9","author":"Wu","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"2026101509311866700_bib297","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40170-023-00307-1","article-title":"Dual inhibition of IDO1\/TDO2 enhances anti-tumor immunity in platinum-resistant non-small cell lung cancer","volume":"11","author":"Wu","year":"2023","journal-title":"Cancer Metab."},{"key":"2026101509311866700_bib298","doi-asserted-by":"publisher","first-page":"101747","DOI":"10.1016\/j.xcrm.2024.101747","article-title":"A PD-1-targeted, receptor-masked IL-2 immunocytokine that engages IL-2R\u03b1 strengthens T cell-mediated anti-tumor therapies","volume":"5","author":"Wu","year":"2024","journal-title":"Cell Rep. Med."},{"key":"2026101509311866700_bib299","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.semcancer.2021.02.013","article-title":"Impact of cancer evolution on immune surveillance and checkpoint inhibitor response","volume":"84","author":"Wu","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"2026101509311866700_bib300","doi-asserted-by":"publisher","first-page":"10503","DOI":"10.1038\/s41467-024-54883-x","article-title":"Thermal-responsive activation of engineered bacteria to trigger antitumor immunity post microwave ablation therapy","volume":"15","author":"Wu","year":"2024","journal-title":"Nat. Commun."},{"key":"2026101509311866700_bib301","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41392-025-02557-5","article-title":"A modular \u201cCatch-and-Play\u201d platform for rapid T-cell engager target assembly for personalised cancer treatment","volume":"11","author":"Xi","year":"2026","journal-title":"Signal Transduct. Target. Ther."},{"key":"2026101509311866700_bib302","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41392-022-01270-x","article-title":"Neoantigens: Promising targets for cancer therapy","volume":"8","author":"Xie","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"2026101509311866700_bib303","doi-asserted-by":"publisher","first-page":"gkaf1171","DOI":"10.1093\/nar\/gkaf1171","article-title":"Single-cell mapping of alternative splicing linked to checkpoint immunotherapy response","volume":"53","author":"Xiong","year":"2025","journal-title":"Nucleic Acids Res."},{"key":"2026101509311866700_bib304","doi-asserted-by":"publisher","first-page":"112829","DOI":"10.1016\/j.isci.2025.112829","article-title":"Bispecific targeting of 4-1BB and CCR8 boosts antitumor immunity via Ti-Treg depletion and CD8+ activation","volume":"28","author":"Xu","year":"2025","journal-title":"iScience"},{"key":"2026101509311866700_bib305","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1038\/s12276-023-01013-0","article-title":"Cancer-associated fibroblasts: From basic science to anticancer therapy","volume":"55","author":"Yang","year":"2023","journal-title":"Exp. Mol. Med."},{"key":"2026101509311866700_bib306","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202405583","article-title":"Modular prodrug-engineered oxygen nano-tank with outstanding nanoassembly performance, high oxygen loading, and closed-loop tumor hypoxia relief","volume":"11","author":"Yang","year":"2024","journal-title":"Adv. Sci. (Weinh)"},{"key":"2026101509311866700_bib307","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s00262-023-03610-4","article-title":"An analysis pipeline for understanding 6-thioguanine effects on a mouse tumour genome","volume":"73","author":"Yankilevich","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"key":"2026101509311866700_bib308","doi-asserted-by":"publisher","first-page":"4622","DOI":"10.1158\/1078-0432.CCR-08-3012","article-title":"MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance","volume":"15","author":"Yip","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"2026101509311866700_bib309","doi-asserted-by":"publisher","first-page":"2622746","DOI":"10.1080\/19420862.2026.2622746","article-title":"Expanding the horizons of cancer therapy with next-generation 4-1BB agonists: A review of molecular and clinical strategies to maximize efficacy and ensure safety","volume":"18","author":"You","year":"2026","journal-title":"MAbs"},{"key":"2026101509311866700_bib310","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.197404","article-title":"DNA delivered by lipid nanoparticles induces CD8+ T cell-dependent antitumor responses and enhances anti-PD-L1 therapy","volume":"11","author":"Yum","year":"2026","journal-title":"JCI Insight"},{"key":"2026101509311866700_bib311","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/s41568-025-00820-z","article-title":"Recent advances in therapeutic cancer vaccines","volume":"25","author":"Zaidi","year":"2025","journal-title":"Nat. Rev. Cancer"},{"key":"2026101509311866700_bib312","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations associated with acquired resistance to PD-1 blockade in melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"2026101509311866700_bib313","doi-asserted-by":"publisher","first-page":"113295","DOI":"10.1016\/j.celrep.2023.113295","article-title":"KEAP1 mutation in lung adenocarcinoma promotes immune evasion and immunotherapy resistance","volume":"42","author":"Zavitsanou","year":"2023","journal-title":"Cell Rep."},{"key":"2026101509311866700_bib314","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.cell.2020.03.048","article-title":"Single-cell analyses inform mechanisms of myeloid-targeted therapies in colon cancer","volume":"181","author":"Zhang","year":"2020","journal-title":"Cell"},{"key":"2026101509311866700_bib315","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202521638","article-title":"Chemically engineered L. Reuteri delivering \u03b1PD-L1 and gallium ions via metal-phenolic networks potentiate anti-tumor immunity and ferroptosis","volume":"13","author":"Zhang","year":"2026","journal-title":"Adv. Sci. (Weinh)"},{"key":"2026101509311866700_bib316","doi-asserted-by":"publisher","first-page":"4081","DOI":"10.1038\/s41467-026-70876-4","article-title":"Reactivating exhausted tumor-infiltrating T cells by a bispecific DC-T cell engager in mice","volume":"17","author":"Zhang","year":"2026","journal-title":"Nat. Commun."},{"key":"2026101509311866700_bib317","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41392-021-00486-7","article-title":"Alternative splicing and cancer: A systematic review","volume":"6","author":"Zhang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"2026101509311866700_bib318","doi-asserted-by":"crossref","first-page":"115999","DOI":"10.1016\/j.isci.2026.115999","article-title":"Alternative splicing regulates FGGY- derived neoantigen presentation and promotes immune evasion in metabolic-associated hepatocellular carcinoma","volume":"29","author":"Zhao","year":"2026","journal-title":"iScience"},{"key":"2026101509311866700_bib319","doi-asserted-by":"publisher","first-page":"1035323","DOI":"10.3389\/fimmu.2022.1035323","article-title":"Manipulation of the crosstalk between tumor angiogenesis and immunosuppression in the tumor microenvironment: Insight into the combination therapy of anti-angiogenesis and immune checkpoint blockade","volume":"13","author":"Zheng","year":"2022","journal-title":"Front. Immunol."},{"key":"2026101509311866700_bib320","doi-asserted-by":"publisher","DOI":"10.1172\/JCI180080","article-title":"Spatial and functional targeting of intratumoral Tregs reverses CD8+ T cell exhaustion and promotes cancer immunotherapy","volume":"134","author":"Zhou","year":"2024","journal-title":"J. Clin. Invest."},{"key":"2026101509311866700_bib321","doi-asserted-by":"publisher","first-page":"115919","DOI":"10.1016\/j.celrep.2025.115919","article-title":"Inhibiting UPF1 methylation enhances tumor immunotherapy sensitivity by reducing nonsense-mediated mRNA decay","volume":"44","author":"Zhu","year":"2025","journal-title":"Cell Rep."},{"key":"2026101509311866700_bib322","doi-asserted-by":"publisher","first-page":"7457","DOI":"10.1038\/s41467-025-62399-1","article-title":"COUP-TFII-mediated reprogramming of the vascular endothelium counteracts tumor immune evasion","volume":"16","author":"Zhu","year":"2025","journal-title":"Nat. Commun."},{"key":"2026101509311866700_bib323","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1111\/pcmr.12943","article-title":"Transient activation of tumoral DNA damage tolerance pathway coupled with immune checkpoint blockade exerts durable tumor regression in mouse melanoma","volume":"34","author":"Zhuo","year":"2021","journal-title":"Pigment Cell Melanoma Res."},{"key":"2026101509311866700_bib324","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1038\/s41568-025-00869-w","article-title":"Unveiling the molecular and immunological drivers of antibody-drug conjugates in cancer treatment","volume":"25","author":"Zippelius","year":"2025","journal-title":"Nat. Rev. Cancer"},{"key":"2026101509311866700_bib325","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1016\/j.immuni.2024.07.020","article-title":"Long-distance microbial mechanisms impacting cancer immunosurveillance","volume":"57","author":"Zitvogel","year":"2024","journal-title":"Immunity"},{"key":"2026101509311866700_bib326","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s41392-025-02269-w","article-title":"CAR-T cell therapy for cancer: Current challenges and future directions","volume":"10","author":"Zugasti","year":"2025","journal-title":"Signal Transduct. Target. Ther."}],"container-title":["Journal of Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/rupress.org\/jem\/article-pdf\/doi\/10.1084\/jem.20260378\/2041932\/jem_20260378.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/rupress.org\/jem\/article-pdf\/doi\/10.1084\/jem.20260378\/2041932\/jem_20260378.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T13:31:34Z","timestamp":1792071094000},"score":1,"resource":{"primary":{"URL":"https:\/\/rupress.org\/jem\/article\/223\/11\/e20260378\/283070\/Turning-cold-tumors-hot-Strategies-to-enhance"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,15]]},"references-count":326,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11,2]]}},"URL":"https:\/\/doi.org\/10.1084\/jem.20260378","relation":{},"ISSN":["0022-1007","1540-9538"],"issn-type":[{"value":"0022-1007","type":"print"},{"value":"1540-9538","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,15]]},"article-number":"e20260378"}}